Eliglustat Tartrate
Who holds supplier records for Eliglustat Tartrate? 7 organisations hold a current record for Eliglustat Tartrate: an active US FDA Type II Drug Master File. Recorded organisation countries for current records: India (6) and Canada (1).
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 13 Nov 2026. How we read these records
Cite as: PharmaTek, “Eliglustat Tartrate: DMF and CEP holder records”, record as of 13 Nov 2026, pharmatek.co.uk/directory/api/eliglustat-tartrate
Reading the evidence
- 7 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- Most recorded organisations are in India
6 of the 7 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.
- 4 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
Current records (7)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Eliglustat Tartrate. Country is the organisation's recorded country, not necessarily the manufacturing site.
- BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITEDIndiaActive DMF 32572, 32860 · latest filing May 2018
- Maithri Laboratories Private LimitedIndia Company GMP cert on recordActive DMF 32653, 32612 · latest filing Mar 2018
- Apotex Inc.CanadaActive DMF 32724 · latest filing May 2018
- Cipla LimitedIndia Company GMP cert on recordActive DMF 32537 · latest filing Mar 2018
- Dr. Reddy's Laboratories Ltd.India Company GMP cert on recordActive DMF 31475 · latest filing Mar 2017
- Hetero Drugs LimitedIndia Company GMP cert on recordActive DMF 41619 · latest filing Dec 2025
- RAKS PHARMA PVT LTDIndiaActive DMF 32303 · latest filing Dec 2017
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Other forms of this substance
A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:
Overview
Eliglustat Tartrate is a glucosylceramide synthase inhibitor used for the long-term treatment of adult patients with Gaucher disease type 1. It works by reducing the amount of glucosylceramide that the body produces, helping to manage the condition.
Chemical identity
- IUPAC name
- bis(N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-pyrrolidin-1-ylpropan-2-yl]octanamide);(2R,3R)-2,3-dihydroxybutanedioic acid
- Canonical SMILES
- CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@@H](C2=CC3=C(C=C2)OCCO3)O.CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@@H](C2=CC3=C(C=C2)OCCO3)O.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O
- InChIKey
- KUBARPMUNHKBIQ-VTHUDJRQSA-N
- Synonyms
- Cerdelga API, cerdelga, cerdelga component eliglustat tartrate, eliglustat hemitartrate, genz 112638, genz-112638
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Glucosylceramide Synthase Inhibitor
- Mechanism of action
- Cytochrome P450 2D6 Inhibitors; Glucosylceramide Synthase Inhibitors; P-Glycoprotein Inhibitors
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Eliglustat Tartrate?
7 organisations hold an active US FDA Type II Drug Master File or a CEP for Eliglustat Tartrate: BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (India), Maithri Laboratories Private Limited (India), Apotex Inc. (Canada), Cipla Limited (India), Dr. Reddy's Laboratories Ltd. (India), Hetero Drugs Limited (India) and RAKS PHARMA PVT LTD (India). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Eliglustat Tartrate Drug Master Files are active?
BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (DMF 32572, 32860), Maithri Laboratories Private Limited (DMF 32653, 32612), Apotex Inc. (DMF 32724), Cipla Limited (DMF 32537), Dr. Reddy's Laboratories Ltd. (DMF 31475), Hetero Drugs Limited (DMF 41619) and RAKS PHARMA PVT LTD (DMF 32303). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
How do I qualify a Eliglustat Tartrate supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Eliglustat Tartrate?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.